Results from the phase 1b CodeBreak 100/1 trial show that administering the novel KRASinhibitor sotorasib alone prior to combining it with an immune checkpoint inhibitor led tolower rates of grade 3-4 treatment-related adverse events compared with beginningadministration of the treatments concurrently.

At 12 months, nivolumab plus chemotherapy yielded a PFS of 89.3% versus 60.7% forchemotherapy alone and an OS of 98.2% compared with 82.1%, respectively. Thecombination improved median PFS by 52% compared with chemotherapy alone at amedian follow-up of 26.1 months. (See also NADIM II and IMpower010 Provide Support for Neoadjuvant and Adjuvant Immunotherapy in Lung Cancer)

A 76-year-old Black woman arrives at the clinic for an evaluation of a slowly increasing bump on her face that she discovered about a year ago, which hasn’t itched, burnt, or caused any other pain. Is it a trichofolliculoma, a hypertrophic scar, basal cell carcinoma, or a cutis osteoma?

After receiving a recently confirmed diagnosis of early-stage nodular sclerosing Hodgkin lymphoma, a 27-year-old woman is evaluated. She has not experienced weight loss, night sweats, or fever. She has an unremarkable medical history and doesn’t use any drugs. What is the best course of action after a physical examination, lab tests, and scans?

The VITAL trial enrolled more than 25,000 men and women over age 50. Supplemental vitamin D showed no significant benefit vs. placebo in preventing the common fractures of osteoporosis.

An efficacy number that’s been widely and unquestioningly quoted by various media organizations — “85% effective” or “at least 85% effective” — is based entirely on a small study done in Africa in the 1980s that has major limitations and with “pretty weak” findings.